Mary Theo’s Post

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

USPTO has proposed amending the patent rules around terminal disclaimers to require that the disclaimed patent will only be enforceable if the patent is not tied and has never been tied to a patent held invalid for lack of novelty or obviousness. Comments on the proposed rule are due July 9. If the rule goes into effect, this could have big repercussions for large patent portfolios which are often linked together by terminal disclaimers. Challengers would be able to invalidate one patent, causing a domino effect invalidating other members of the portfolio that have been terminally disclaimed over the challenged patent. Read more in the post by Karen G. Potter and Jeff Schmidt, PhD, MBA, JD on the MoFo Life Sciences Blog. https://lnkd.in/gEk4A66B

The early bird pricing for the American Conference Institute's 22nd Advanced Summit on Life Science Patents expires THIS FRIDAY - take advantage! 2024 conference highlights include: - Establishing sound and successful protocols to procure and enforce life sciences patents in the U.S. and internationally - Mastering the art of claim balance and disclosure, drawing on lessons from patents and cases in the year post-Amgen v Sanofi - Re-evaluating the “pros and cons” of opting-into the EU’s Unitary Patent system, including a discussion of the first preliminary injunction granted by the Unified Patent Court (UPC) - And so much more! Details here: https://lnkd.in/dGZkuGWK #ACIConferences #lifesciences #patents #intellectualproperty